טוען...
Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
INTRODUCTION: Childhood chronic myeloid leukemia (CML) accounts for less than 3% of all childhood leukemias, hence, data on imatinib (IM) in adult CML patients has been largely extrapolated to children. We have analyzed our data to add to the existing literature. AIMS: Primary objective is to assess...
שמור ב:
| הוצא לאור ב: | South Asian J Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Medknow Publications & Media Pvt Ltd
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4236696/ https://ncbi.nlm.nih.gov/pubmed/25422804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2278-330X.142961 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|